You are now a lot of the way there. The goal is to do this kind of analysis all the way down for all of your variables, finding why there is any odd data - negatives, NaN, zeros, etc. You can use filters, look at the data, summary stats, etc.
Now, we are going to identify the high performing companies using the same categories for criteria.
We recommend selling Daily Journal Corporation (NasdaqCM:DJCO) and Cara Therapeutics, Inc. (NasdaqGM:CARA). We selected these companies based on poor key financial health criteria, coupled with having a high EV/EBITDA multiple, and negative industry outlooks. Poor performing companies were in the bottom quartile of EBITDA, profit margin, profit, roc, and EBITDA margin, within the entire dataset. Daily Journal has an EV/EBITDA multiple of 95.87, the fourth highest in the poor performing quartile – indicating a high valuation with comparatively low EBITDA. Furthermore, as a news publishing company operating on a regional basis, we see strong industry headwinds of full digitization as an obstacle to company growth (CFRA Equity Research: DJCO, 11/20/21). Cara Therapeutics has an EV/EBITDA multiple of 201.06, the second highest in the poor performing quartile. We see the same trend here as we do with Daily Journal Corporation, only more exacerbated. Additionally, recent company news reports revealed abnormalities for patients involved in their clinical trials for Oral KORUSVA (Company Press Release: CARA, 4/29/21). Specifically, we believe that the company faces inconsistent growth, in addition to poor operating and return on investment margins (Argus Research Report: CARA, 11/10/21).
We recommend buying Merck & Co (NYSE: MRK) and Nvidia Corporation (NasdaqGS: NVDA). We selected these companies because they have a relatively lower (hence healthier) EV/EBITDA multiple, while also they are high performing so we would recommend buying those stocks. The division of EV by EBITDA gives a good measure of value. It estimates the number of years in which the business will repay its acquisition cost to the buyer through its earnings. Merck&Co has an EV/EBITDA multiple of 11.35, the 13th from the end in our data frame. This indicates that although it's not at the top of the high performers group, it's still considered to be a buy since it has a good EV/EBITDA compared to the firms in it's industry. Nvidia has a high EV/EBITDA multiple of 60.36, which should be encouraging to a potential investor due to previously discussed positive performance implications. This is the highest multiple in the top performing companies and represents a company with ample room for future growth. Nvidia is an artificial intelligence company with promising future earnings expectations based on our multiple analysis. Following the pandemic chip storage, the demand for Nvidia's chips for self-driving cars sky rocketed. The company is looking to expand chip supply to other industries such as healthcare and entertainment. (Investor's Business Daily: NVDA, 11/18/21).